Clinical trials
3 active studies led by Annovis Bio Inc., of 8 in all
Source: ClinicalTrials.gov, Studies with Annovis Bio Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 3Markets in public records
- 0Regions & countries
- 3Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Annovis Bio Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Annovis Bio Inc.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NYSE: ANVS
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1477845. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1477845.
Trials over time
Studies Annovis Bio Inc. leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Annovis Bio Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Annovis Bio Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Annovis Bio Inc. is in.
From our blog
Stories on the topics Annovis Bio Inc. works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read